Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07665268 · ClinicalTrials.gov registry record · Phase 4
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.
A Phase 4 study, sponsored by Sequence LifeScience.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 2,000
- Enrollment target
NCT07665268 is a Phase 4 study that is actively recruiting participants, run by Sequence LifeScience. The registered enrollment target is 2,000 participants.
The verdict
NCT07665268, a Phase 4 study, is actively recruiting participants, sponsored by Sequence LifeScience.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
A multicenter prospective modified platform trial evaluating several cellular, acellular, and matrix like products and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
Interventions
- OTHER Activate™ Matrix + SOC
- OTHER AmnioDefend™ FT Matrix + SOC
- OTHER Palisade™ DM Matrix + SOC
- OTHER Sentry™ SL Matrix + SOC
- OTHER Shelter™ DM Matrix + SOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-28 |
| Est. Completion | 2028-01-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07665268
The ClinicalTrials.gov registry entry for NCT07665268 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequence LifeScience, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Activate™ Matrix + SOC is the first listed.
NCT07665268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07665268 about?
NCT07665268 is a clinical study titled "Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers.". A multicenter prospective modified platform trial evaluating several cellular, acellular, and matrix like products and standard of care versus matched standard of care controls in the management of nonhealing pressure ulcers.
What is the current status of trial NCT07665268?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 2,000 participants. The study started on 2026-01-28. Estimated completion is 2028-01-28.
What interventions are being tested in trial NCT07665268?
The interventions under investigation include: Activate™ Matrix + SOC (OTHER), AmnioDefend™ FT Matrix + SOC (OTHER), Palisade™ DM Matrix + SOC (OTHER), Sentry™ SL Matrix + SOC (OTHER), Shelter™ DM Matrix + SOC (OTHER).
Who is sponsoring clinical trial NCT07665268?
This trial is sponsored by Sequence LifeScience, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.